CELL INTELLIGENCE · 肿瘤细胞治疗研究

用于广泛抗癌免疫治疗的高亲和力抗 ROR1 可变区的开发

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.

平行处理 T 细胞与 NK 细胞以增强体内 CAR-T 细胞对血液肿瘤和实体瘤的活性

Parallel processing of T cells and natural killer cells to enhance in vivoCAR T cell activity against blood and solid cancers.

本研究鼓励优化利用白细胞单采产物。通过将废弃的 PBMC 回收为 NK 细胞，可有效增强 CAR-T 细胞疗法，改善肿瘤清除率和生存率。

放疗通过激活 NF-κB/Icam1 信号增强 EGFR 靶向 CAR-T 细胞对三阴性乳腺癌的疗效

Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.

肿瘤相关 Tn 和 STn 抗原：从分子机制到精准诊断与治疗

Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment.

Tn/STn 抗原在肿瘤发生和免疫逃逸中发挥关键作用，在诊断和治疗方面具有巨大潜力。未来研究应集中于阐明其潜在机制、开发创新检测技术，并促进多学科合作，以推动基于 Tn/STn 抗原的肿瘤分子分型、精准靶向治疗和疗效预测系统的发展，从而为癌症诊断和治疗提供新方向。

乳腺癌中的免疫检查点阻断与新兴联合平台：叙述性综述

Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review.

乳腺癌管理的新策略：从治疗到长期缓解

Novel strategies in breast cancer management: From treatment to long-term remission.

乳腺癌 CAR 免疫治疗：特殊性、在研探索与未来策略

CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.

乳腺癌中基于嵌合抗原受体的免疫治疗：中国近期进展

Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.

对三阴性乳腺癌有效的新一代 CD44v6 特异性 CAR-NK 细胞

Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer.

构建具有优越抗肿瘤疗效的分泌可溶性程序性细胞死亡蛋白的 HER2-CAR-NK 细胞

Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.